Aggressive therapy set for patients with early stage of breast cancer
An aggressive new therapy that attacks an especially perilous early-stage breast cancer is ready for use on patients.
That, at least, is what's cited in an October-November AARP Magazine story regarding a type of cancer known as HER2+ER+.
The multi-disciplinary therapy was first proven beneficial in later stages of the disease, says the piece.
The article also notes that "about a quarter of all breast cancers are HER2+" — tumors that have "higher levels of a protein called human epidermal growth factor receptor 2, which tends to make them grow and spread faster than other kinds of breast cancer."
|Dr. Vered Stearns|